$LFMD
LifeMD, Inc. Stock $lfmd

$lfmd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224009581 Filed on March 11, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$44.14M	$44.86M	$152.5M
YoY Change	33.26%	59.53%	28.15%
Cost Of Revenue	$4.600M	$5.356M	$18.90M
YoY Change	9.14%	31.66%	1.25%
Gross Profit	$39.54M	$39.50M	$133.6M
YoY Change	36.78%	64.25%	33.16%
Gross Profit Margin	89.58%	88.06%	87.61%
Selling, General & Admin	$39.48M	$38.24M	$128.1M
YoY Change	44.51%	36.68%	2.25%
% of Gross Profit	99.84%	96.8%	95.88%
Research & Development	$2.087M	$1.998M	$6.061M
YoY Change	76.35%	96.05%	104.04%
% of Gross Profit	5.28%	5.06%	4.53%
Depreciation & Amortization	$65.92K	$1.941M	$204.0K
YoY Change	38.33%	56.57%	25.99%
% of Gross Profit	0.17%	4.91%	0.15%
Operating Expenses	$45.72M	$41.68M	$148.1M
YoY Change	43.92%	61.48%	3.01%
Operating Profit	-$6.171M	-$2.172M	-$14.49M
YoY Change	116.32%	23.64%	-66.65%
Interest Expense	$477.7K	-$622.7K	$2.597M
YoY Change	80.62%	-26.18%	103.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.649M	-$2.794M	-$17.41M
YoY Change	93.14%	-75.08%	-61.01%
Income Tax		$428.0K	$428.0K
% Of Pretax Income
Net Earnings	-$6.768M	-$4.509M	-$20.60M
YoY Change	68.85%	-64.53%	-54.77%
Net Earnings / Revenue	-15.33%	-10.05%	-13.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.19	-$0.12	-$0.70
COMMON SHARES
Basic Shares Outstanding	40.37M shares	37.98M shares	33.91M shares
Diluted Shares Outstanding	39.24M shares		33.91M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$35.11M	$33.15M	$33.15M
YoY Change	204.65%	737.26%	737.26%
Cash & Equivalents	$35.11M	$33.15M
Short-Term Investments
Other Short-Term Assets	$1.299M	$934.5K	$1.420M
YoY Change	20.92%	36.02%	74.43%
Inventory	$2.374M	$2.760M	$2.760M
Prepaid Expenses
Receivables	$5.336M	$5.277M	$5.277M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$44.41M	$42.60M	$42.60M
YoY Change	131.72%	276.65%	276.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$586.0K	$476.3K	$1.071M
YoY Change	26.71%	-0.03%	-36.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$17.05M	$15.88M	$15.88M
YoY Change	15.92%	10.6%	10.6%
TOTAL ASSETS
Total Short-Term Assets	$44.41M	$42.60M	$42.60M
Total Long-Term Assets	$17.05M	$15.88M	$15.88M
Total Assets	$61.46M	$58.48M	$58.48M
YoY Change	81.45%	127.85%	127.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.40M	$11.08M	$11.08M
YoY Change	79.56%	9.68%	9.68%
Accrued Expenses	$14.56M	$13.94M	$11.95M
YoY Change	25.74%	14.56%	16.51%
Deferred Revenue
YoY Change
Short-Term Debt	$115.9K	$327.6K	$327.6K
YoY Change	-93.64%	-88.29%	-88.29%
Long-Term Debt Due	$3.958M
YoY Change
Total Short-Term Liabilities	$44.68M	$34.78M	$34.78M
YoY Change	65.35%	10.86%	10.86%
LONG-TERM LIABILITIES
Long-Term Debt	$14.07M	$17.93M	$17.93M
YoY Change	4.82%
Other Long-Term Liabilities	$1.411M	$205.1K	$205.1K
YoY Change	78.87%	-87.16%	-87.16%
Total Long-Term Liabilities	$15.48M	$18.13M	$18.13M
YoY Change	8.93%	1035.28%	1035.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.68M	$34.78M	$34.78M
Total Long-Term Liabilities	$15.48M	$18.13M	$18.13M
Total Liabilities	$60.16M	$52.91M	$54.98M
YoY Change	45.9%	60.49%	69.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$221.8M	-$214.3M
YoY Change	13.57%	12.43%
Common Stock	$407.3K	$383.6K
YoY Change	27.13%	21.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$163.7K	$163.7K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$845.3K	$3.505M	$3.505M
YoY Change
Total Liabilities & Shareholders Equity	$61.46M	$58.48M	$58.48M
YoY Change	81.45%	127.85%	127.85%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.768M	-$4.509M	-$20.60M
YoY Change	68.85%	-64.53%	-54.77%
Depreciation, Depletion And Amortization	$65.92K	$1.941M	$204.0K
YoY Change	38.33%	56.57%	25.99%
Cash From Operating Activities	$5.202M	$5.714M	$8.820M
YoY Change	-299.02%	-390.17%	-138.46%
INVESTING ACTIVITIES
Capital Expenditures	$175.6K	$2.217M	$203.8K
YoY Change	421.73%	25.16%	-44.41%
Acquisitions
YoY Change
Other Investing Activities		$1.130K	-$148.9K
YoY Change			-97.03%
Cash From Investing Activities	-$2.190M	-$2.217M	-$8.733M
YoY Change	20.9%	25.16%	-37.2%
FINANCING ACTIVITIES
Cash Dividend Paid	$776.6K		$3.106M
YoY Change	0.0%		0.0%
Common Stock Issuance & Retirement, Net			$10.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.048M	14.36M	$29.10M
YoY Change	-108.74%	671.21%	-5609.43%
NET CHANGE
Cash From Operating Activities	$5.202M	5.714M	$8.820M
Cash From Investing Activities	-$2.190M	-2.217M	-$8.733M
Cash From Financing Activities	-$1.048M	14.36M	$29.10M
Net Change In Cash	$1.964M	17.86M	$29.19M
YoY Change	-74.04%	-1051.0%	-178.11%
FREE CASH FLOW
Cash From Operating Activities	$5.202M	$5.714M	$8.820M
Capital Expenditures	$175.6K	$2.217M	$203.8K
Free Cash Flow	$5.027M	$3.497M	$8.616M
YoY Change	-289.85%	-193.5%	-136.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000948320
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2023Q4	LFMD	Purchase Price Payable PurchasePricePayable		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2023	LFMD	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration		usd
CY2022	LFMD	Stock Issued During Period Value Cashless Exercise Of Stock Options StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions		usd
CY2023	LFMD	Stock Issued During Period Value Cashless Exercise Of Stock Warrants StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants		usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	LFMD	Sales Returns Reserve SalesReturnsReserve		usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1		usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	LFMD	Sale Of Common Stock SaleOfCommonStock		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	LFMD	Cashless Exercise Of Warrants CashlessExerciseOfWarrants		usd
CY2023	LFMD	Consideration Payable For Cleared Acquisition ConsiderationPayableForClearedAcquisition		usd
CY2023	LFMD	Consideration Payable For Resumebuild Acquisition ConsiderationPayableForResumebuildAcquisition		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	LFMD	Stock Issued For Debt Conversion StockIssuedForDebtConversion		usd
CY2022	LFMD	Series B Preferred Stock Conversion SeriesBPreferredStockConversion		usd
CY2023	LFMD	Principal Of Paycheck Protection Program Loans Forgiven PrincipalOfPaycheckProtectionProgramLoansForgiven		usd
CY2022	LFMD	Non Cash Warrants Issued For Debt Instruments NonCashWarrantsIssuedForDebtInstruments		usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount		usd
CY2022	us-gaap	Income Tax Reconciliation Deductions Dividends IncomeTaxReconciliationDeductionsDividends		usd
CY2022	LFMD	Income Tax Reconciliation Rate Differential IncomeTaxReconciliationRateDifferential		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39785
CY2023	dei	Entity Registrant Name EntityRegistrantName	LIFEMD, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0238453
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	236 Fifth Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
CY2023	dei	City Area Code CityAreaCode	(866)
CY2023	dei	Local Phone Number LocalPhoneNumber	351-5907
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	111775534	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40366047	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum
CY2023	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33146725	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3958957	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5277250	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2834750	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	485850	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	127265	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2759932	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3703363	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	934510	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	687022	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	42604267	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11311357	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	476303	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	476441	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	594897	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1206009	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	11795979	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	8840187	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3009263	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3831859	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	15876442	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	14354496	usd
CY2023Q4	us-gaap	Assets Assets	58480709	usd
CY2022Q4	us-gaap	Assets Assets	25665853	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11084855	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10106793	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13937494	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12166509	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	327597	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2797250	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	603180	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	756093	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8828598	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5547506	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34781724	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31374151	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	17927727	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73849	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	574136	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	131250	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	443750	usd
CY2022Q4	LFMD	Purchase Price Payable PurchasePricePayable	579319	usd
CY2023Q4	us-gaap	Liabilities Liabilities	52914550	usd
CY2022Q4	us-gaap	Liabilities Liabilities	32971356	usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4565822	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	140	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	140	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38358641	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31552775	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38255601	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31449735	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	383586	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	315528	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217550583	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	179015250	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-214265236	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190562994	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	103040	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	103040	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	163701	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	163701	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3505372	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11395777	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	2060787	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-475548	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5566159	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11871325	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58480709	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25665853	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152547006	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119033520	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	18900464	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	18668028	usd
CY2023	us-gaap	Gross Profit GrossProfit	133646542	usd
CY2022	us-gaap	Gross Profit GrossProfit	100365492	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	76451466	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	78369430	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	51694232	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46960782	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	6297321	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	6717795	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	7632283	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	5033468	usd
CY2023	us-gaap	Development Costs DevelopmentCosts	6060513	usd
CY2022	us-gaap	Development Costs DevelopmentCosts	2970202	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	8862596	usd
CY2022	LFMD	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	5101000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	148135815	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	143813273	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-14489273	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-43447781	usd
CY2023	us-gaap	Interest Expense InterestExpense	2596586	usd
CY2022	us-gaap	Interest Expense InterestExpense	1275946	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-325198	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	63400	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17411057	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44660327	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	428000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360700	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-17839057	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-45021027	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2756935	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	514632	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20595992	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-45535659	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3106250	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3106250	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23702242	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48641909	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.70
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.57
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.70
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.57
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33905155	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30976455	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33905155	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30976455	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	21708288	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	13734614	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	90400	usd
CY2022	LFMD	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	38500	usd
CY2022	LFMD	Stock Issued During Period Value Legal Settlement StockIssuedDuringPeriodValueLegalSettlement	816000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	3106250	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	144000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	12150	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-45021027	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11871325	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11871325	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12489343	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	94500	usd
CY2023	LFMD	Stock Issued During Period Value Noncontingent Consideration Payment StockIssuedDuringPeriodValueNoncontingentConsiderationPayment	2568000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	532000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	873100	usd
CY2023	LFMD	Sale Of Common Stock Under Atm Net SaleOfCommonStockUnderAtmNet	6202659	usd
CY2023	LFMD	Stock Issued For Debt Instruments StockIssuedForDebtInstruments	1000000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10000000	usd
CY2023	LFMD	Stock Issued During Period Value Legal Preferred Stock Conversion StockIssuedDuringPeriodValueLegalPreferredStockConversion	-5072814	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	3106250	usd
CY2023	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	144000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-305625	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-17839057	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5566159	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5566159	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-17839057	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-45021027	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	333939	usd
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	5424810	usd
CY2022	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	2681807	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	971464	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	926542	usd
CY2023	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	167221	usd
CY2022	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	273822	usd
CY2023	us-gaap	Depreciation Depreciation	203952	usd
CY2022	us-gaap	Depreciation Depreciation	161885	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	537685	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	103417	usd
CY2022	LFMD	Sales Returns Reserve SalesReturnsReserve	338193	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-325198	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	63400	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5101000	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	8862596	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	354000	usd
CY2023	LFMD	Operating Lease Payments Adjustments OperatingLeasePaymentsAdjustments	766280	usd
CY2022	LFMD	Operating Lease Payments Adjustments OperatingLeasePaymentsAdjustments	546439	usd
CY2023	LFMD	Stock Issued For Legal Settlement StockIssuedForLegalSettlement	532000	usd
CY2022	LFMD	Stock Issued For Legal Settlement StockIssuedForLegalSettlement	816000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	12489343	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	13734614	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2442500	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2192888	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	358585	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-76291	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-405746	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2183012	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	247488	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-106168	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-808368	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-455805	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3281092	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4047626	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	978062	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1251037	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4678757	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1309968	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-579319	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-888486	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8820232	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22935149	usd
CY2023	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	8380602	usd
CY2022	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	8526205	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	203814	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	366633	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	148868	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4000500	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1012395	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8733284	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13905733	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	19466887	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2347691	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2906000	usd
CY2023	LFMD	Sale Of Common Stock SaleOfCommonStock	6202659	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	38500	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	94500	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	90400	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	3106250	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	3106250	usd
CY2023	LFMD	Net Payments For Membership Interest In Worksimpli NetPaymentsForMembershipInterestInWorksimpli	-305625	usd
CY2022	LFMD	Net Payments For Membership Interest In Worksimpli NetPaymentsForMembershipInterestInWorksimpli	12150	usd
CY2023	LFMD	Payments To Acquire Productive Asset PaymentsToAcquireProductiveAsset	312500	usd
CY2022	LFMD	Payments To Acquire Productive Asset PaymentsToAcquireProductiveAsset	156250	usd
CY2023	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	144000	usd
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	144000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5142542	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	168750	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29100820	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-528200	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29187768	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37369082	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3958957	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41328039	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33146725	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3958957	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2148454	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	189000	usd
CY2023	LFMD	Cashless Exercise Of Options CashlessExerciseOfOptions	744	usd
CY2022	LFMD	Cashless Exercise Of Options CashlessExerciseOfOptions	297	usd
CY2023	LFMD	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	793	usd
CY2022	LFMD	Consideration Payable For Cleared Acquisition ConsiderationPayableForClearedAcquisition	8079367	usd
CY2022	LFMD	Consideration Payable For Resumebuild Acquisition ConsiderationPayableForResumebuildAcquisition	500000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	2568000	usd
CY2023	LFMD	Stock Issued For Debt Conversion StockIssuedForDebtConversion	1000000	usd
CY2023	LFMD	Series B Preferred Stock Conversion SeriesBPreferredStockConversion	5072814	usd
CY2022	LFMD	Principal Of Paycheck Protection Program Loans Forgiven PrincipalOfPaycheckProtectionProgramLoansForgiven	63400	usd
CY2023	LFMD	Non Cash Warrants Issued For Debt Instruments NonCashWarrantsIssuedForDebtInstruments	873100	usd
CY2023	LFMD	Right Of Use Asset RightOfUseAsset	155168	usd
CY2022	LFMD	Right Of Use Asset RightOfUseAsset	89595	usd
CY2023	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	155168	usd
CY2022	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	94168	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_800_eus-gaap--NatureOfOperations_zYw7003mJqYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82C_zS8jylnEnNcc">NATURE OF THE ORGANIZATION AND BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate History</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD, Inc. was formed in the State of Delaware on May 24, 1994, under its prior name, Immudyne, Inc. The Company changed its name to Conversion Labs, Inc. on June 22, 2018 and then subsequently, on February 22, 2021, it changed its name to LifeMD, Inc. Effective February 22, 2021, the trading symbol for the Company’s common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20210222_zpbvWLBcnKU2" title="Common stock per share">0.01</span> per share on The Nasdaq Stock Market LLC changed from “CVLB” to “LFMD”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2016, the original operating agreement of Immudyne PR LLC (“Immudyne PR”), a joint venture to market the Company’s skincare products, was amended and restated and the Company increased its ownership and voting interest in Immudyne PR to <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20160401__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ImmudynePrLlcMember_zK92UgsWvjj3" title="Equity method investment, ownership percentage">78.2</span>%. Concurrent with the name change of the parent company to Conversion Labs, Inc., Immudyne PR was renamed to Conversion Labs PR LLC (“Conversion Labs PR”). On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety to increase the Company’s ownership and voting interest in Conversion Labs PR to <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPrMember_z85qoQ7ZMgr4" title="Equity method investment, ownership percentage">100</span>%. On February 22, 2021, concurrent with the name of the parent company to LifeMD, Inc., Conversion Labs PR was renamed to LifeMD PR, LLC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2018, the Company closed the strategic acquisition of <span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180630__us-gaap--BusinessAcquisitionAxis__custom--LegalSimpliSoftwareLlcMember_zuRxnMtdEF3" title="Voting interests acquired">51</span>% of LegalSimpli Software, LLC, which operates a software as a service application for converting, editing, signing, and sharing PDF documents called PDFSimpli. In addition to LegalSimpli Software, LLC’s growth business model, this acquisition added deep search engine optimization and search engine marketing expertise to the Company. On July 15, 2021, LegalSimpli Software, LLC, changed its name to WorkSimpli Software LLC, (“WorkSimpli”). Effective January 22, 2021, the Company consummated a transaction to restructure the ownership of WorkSimpli (the “WSS Restructuring”) concurrently increased its ownership interest in WorkSimpli to <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_z2TbAHv6GwLl">85.58</span>%. Effective September 30, 2022, two option agreements were exercised which further restructured the ownership of WorkSimpli. As a result, the Company’s ownership interest in WorkSimpli decreased to <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_z6bMDN3gZ7s3">73.64</span>%. Effective December 15, 2022, LifeMD PR, LLC merged into WorkSimpli, with WorkSimpli being the surviving entity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective March 31, 2023, the Company redeemed <span id="xdx_90E_ecustom--NumberOfMembershipInterestUnitsRedeemed_c20230101__20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zfOcsCIEY9z1" title="Number of membership interest units redeemed">500</span> membership interest units in WorkSimpli and, as a result, the Company’s ownership interest in WorkSimpli increased to <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zkSdwtzXjPn1" title="Ownership Interest">74.06</span>%. Effective June 30, 2023, an option agreement was exercised which further restructured the ownership of WorkSimpli. As a result, the Company’s ownership interest in WorkSimpli decreased to <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPRLLCMember__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zMUzJbsYrzu8" title="Ownership interest">73.32</span>%. See Note 8 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2022, the Company acquired Cleared Technologies, PBC, a Delaware public benefit corporation (“Cleared”), a nationwide allergy telehealth platform that provides personalized treatments for allergy, asthma, and immunology (See Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nature of Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a direct-to-patient telehealth company providing a high-quality, cost-effective, and convenient way to access comprehensive, virtual and in-home healthcare. The Company believes the traditional model of visiting a doctor’s office, traveling to a retail pharmacy, and returning for follow up care or prescription refills is complex, inefficient, and costly, and discourages many individuals from seeking medical care. The Company is improving the delivery of healthcare through telehealth with our proprietary technology platform, affiliated-and-dedicated provider network, broad and expanding treatment capabilities, and unique ability to nurture patient relationships. Direct-to-patient telehealth technology companies, like the Company, connect consumers to affiliated, licensed, healthcare professionals for care across numerous indications, including urgent and primary care, weight management, sleep, hair loss, men’s and women’s health, hormonal therapy and dermatology, chronic care management and more.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s telehealth platform helps patients access their licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis. In addition to its telehealth prescription offerings, the Company sells over-the-counter (“OTC”) products. All products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. This creates convenience and often discounted pricing opportunities for patients and recurring revenue streams for the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With its first brand, ShapiroMD, the Company has built a full line of proprietary OTC products for male and female hair loss—including Food and Drug Administration (“FDA”) approved OTC minoxidil and an FDA-cleared medical device—and now a personalized telehealth platform offering that gives consumers access to virtual medical treatment from their providers and, when appropriate, a full line </span>of oral and topical prescription medications for hair loss. The Company’s men’s brand, RexMD, currently offers access to provider-based treatment for erectile dysfunction, as well as treatment for other common men’s health issues, including premature ejaculation and hair loss. In the first quarter of 2021, the Company launched NavaMD, a tele-dermatology and skincare brand for women. The Company has built a platform that allows it to efficiently launch telehealth and wellness product lines wherever it determines there is a market need.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In the first quarter of 2022, we launched our virtual primary care offering under the LifeMD brand, LifeMD Primary Care. This offering provides patients with 24/7 access to an affiliated high-quality provider for their primary care, urgent care, and chronic care needs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In April 2023, we launched our GLP-1 Weight Management program providing primary care, weight loss, holistic healthcare, lab work and prescription services, as appropriate, to patients seeking to access a medically supported weight loss solution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business and Subsidiary History</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2018, the Company closed the strategic acquisition of <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20180630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zd2gwGd7afoc">51</span>% of WorkSimpli. As a result of various ownership restructurings, the Company’s ownership interest in WorkSimpli is <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zswUbFQvab9c">73.32</span>% as of December 31, 2023. See Note 8 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2022, the Company acquired Cleared, a nationwide allergy telehealth platform that provides personalized treatments for allergy, asthma, and immunology. Under the terms of the agreement, the Company acquired all outstanding shares of Cleared at closing in exchange for a $<span id="xdx_904_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn3n3_c20220117__20220118_zBr0AxmslGo8" title="Payments to acquire businesses, net of cash acquired">460</span> thousand upfront cash payment, and two non-contingent milestone payments for a total of $<span id="xdx_909_ecustom--MileStonePayment_pn4n6_c20220117__20220118_zrJToAT6QR0h" title="Milestone payments">3.46</span> million ($<span id="xdx_90A_ecustom--MileStonePayment_pn4n6_c20220117__20220118__srt--StatementScenarioAxis__custom--FirstAndSecondAnniversariesMember_zvHRIMiIxJc1" title="Milestone payments">1.73</span> million each on or before the first and second anniversaries of the closing date). The Company purchased a convertible note from a strategic pharmaceutical investor for $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_pn3n3_c20220117__20220118_z7al22Z8NnS9" title="Conversion of stock converted">507</span> thousand which was converted upon closing of the Cleared acquisition. The Company also agreed to a performance-based earnout based on Cleared’s future net sales, payable in cash or shares at the Company’s discretion. On February 4, 2023, the Company entered into the First Amendment (the “Cleared First Amendment”) to the Stock Purchase Agreement, dated January 11, 2022, between the Company and the sellers of Cleared (the “Cleared Stock Purchase Agreement”). The Cleared Stock Purchase Agreement was amended to, among other things: (i) reduce the total purchase price by $<span id="xdx_900_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn3n3_c20230204__20230204__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zxTlo4Gh9Mki" title="Payments to acquire businesses, net of cash acquired">250</span> thousand to a total of $<span id="xdx_903_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn4n6_c20230204__20230204__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zjQBXVOyT5Uh" title="Payments to acquire businesses, net of cash acquired">3.67</span> million; (ii) change the timing of the payment of the purchase price to $<span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230204__20230204__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_z3YvPqs9bBrg" title="Payments to acquire businesses, gross">460</span> thousand paid at closing (which has already been paid by the Company), with the remaining amount to be paid in five quarterly installments beginning on or before February 6, 2023 and ending January 15, 2024; (iii) removing all “earn-out” payments payable by the Company to the sellers; and (iv) remove certain representations and warranties of the Company and sellers in connection with the transaction (See Note 3). The Company issued the following shares of common stock to the sellers of Cleared under the Cleared First Amendment: (1) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230205__20230206__us-gaap--AwardTypeAxis__custom--FirstOfFiveQuarterlyInstallmentMember_zLiqyJINaQJj" title="Stock issued during period shares new issues">337,895</span> shares on February 6, 2023, (2) <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230416__20230417__us-gaap--AwardTypeAxis__custom--SecondOfFiveQuarterlyInstallmentMember_zFkfdAmBbeSe" title="Stock issued during period shares new issues">455,319</span> shares on April 17, 2023, (3) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230716__20230717__us-gaap--AwardTypeAxis__custom--ThirdOfFiveQuarterlyQuarterlyInstallmentMember_zZ4J3JQatA6g" title="Stock issued during period shares new issues">158,129</span> shares on July 17, 2023, (4) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231017__20231017__us-gaap--AwardTypeAxis__custom--ThirdOfFiveQuarterlyQuarterlyInstallmentMember_zbxMn2yo5kRd" title="Stock issued during period shares new issues">117,583</span> shares on October 17, 2023 and (5) <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240116__20240116__us-gaap--AwardTypeAxis__custom--ThirdOfFiveQuarterlyQuarterlyInstallmentMember_zhmzjrWqf1aj" title="Stock issued during period shares new issues">95,821</span> shares on January 16, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, WorkSimpli closed on an Asset Purchase Agreement (the “ResumeBuild APA”) with East Fusion FZCO, a Dubai, UAE corporation (the “Seller”), whereby WorkSimpli acquired substantially all of the assets associated with the Seller’s business, offering subscription-based resume building software through software as a service online platforms (the “Acquisition”). WorkSimpli paid $<span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zVXWQTGCMfYj" title="Consideration paid">4.0</span> million to the Seller upon closing. The Seller is also entitled to a minimum of $<span id="xdx_90E_ecustom--BusinessAcquisitionPeriodicPayments_pn5n6_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zQm8QOYaybk3" title="Business acquisition periodic payments">500</span> thousand to be paid out in quarterly payments equal to the greater of <span id="xdx_906_ecustom--PercentageOfPaymentAcquistion_pid_dp_uPure_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z2WRXW9sQDXf" title="Percentage of payment acquistion">15</span>% of net profits (as defined in the ResumeBuild APA) or $<span id="xdx_902_ecustom--AssetAcquisitionClosing_c20220201__20220228_zgmuoQmpd7Xg" title="Asset acquisition closing">62,500</span>, for a two-year period ending on the two-year anniversary of the closing of the Acquisition. As of December 31, 2023, WorkSimpli has paid the Seller approximately $<span id="xdx_908_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zPlkvad2rHfh" title="Consideration paid">469</span> thousand in accordance with the ResumeBuild APA. WorkSimpli borrowed the purchase price from the Company pursuant to a promissory note with the obligation secured by an equity purchase guarantee agreement and a stock option pledge agreement from Fitzpatrick Consulting, LLC and its sole member Sean Fitzpatrick, who is Co-Founder and President of WorkSimpli (See Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated, the terms “LifeMD,” “Company,” “we,” “us,” and “our” refer to LifeMD, Inc. (formerly known as Conversion Labs, Inc.), Cleared, a Delaware public benefit corporation and our majority-owned subsidiary, WorkSimpli. The affiliated network of medical Professional Corporations and medical Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C., (“LifeMD PC”) is the Company’s affiliated, variable interest entity in which we hold a controlling financial interest. Unless otherwise specified, all dollar amounts are expressed in United States dollars.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity Evaluation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company has an accumulated deficit approximating $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zqvbtJ7L7qId">214.3</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and has experienced significant losses from its operations. Although the Company is showing significant positive revenue trends, the Company expects to incur further losses through 2024. However, losses have improved significantly, and the Company expects these losses to continue to improve. Additionally, the Company expects its burn rate of cash to continue to improve and to maintain positive operating cash flows for the next 12 months following the date of this report. To date, the Company has been funding operations primarily through the sales of its products, issuance of common and preferred stock, and through loans and advances. The Company’s continued operations are dependent upon obtaining an increase in its sale volumes and obtaining funding from third-party sources or the issuance of additional shares of common stock. There can be no assurances that we will be successful in increasing revenues, improving operational efficiencies, or that financing will be available or, if available, that such financing will be available under favorable terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2023, the Company entered into and closed on a loan and security agreement (the “Avenue Credit Agreement”), and a supplement to the Credit Agreement (the “Avenue Supplement”), with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (collectively, “Avenue”). The Avenue Credit Agreement provides for a convertible senior secured credit facility of up to an aggregate amount of $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zgttIqFgq34k" title="Credit facility">40</span> million, comprised of the following: (1) $<span id="xdx_904_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230320__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zNS5xUZHYaXc" title="Proceeds from line of credit">15</span> million in term loans funded at closing, (2) $<span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230926__20230926__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zDb8dSqzkbC2" title="Proceeds from line of credit">5</span> million of additional committed term loans which the Company received on September 26, 2023 under the First Amendment to the Avenue Credit Agreement (the “Avenue First Amendment”) and (3) $<span id="xdx_909_ecustom--LinesOfCreditUncommittedTremLoan_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zi8tDdpnx3Dc" title="Uncommitted term loans">20</span> million of additional uncommitted term loans, collectively referred to as the “Avenue Facility”. The Avenue Facility matures on <span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zbZM9MIA75w1" title="Line of credit, expiration date">October 1, 2026</span>. The Company issued Avenue warrants to purchase $<span id="xdx_90F_ecustom--WarrantToPurchaseStockValue_pn5n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zbpTLmWqDyxb" title="Warrants to purchase">1.2</span> million of the Company’s common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zwsuZYTdscg4" title="Warrants exercise price">1.24</span>, subject to adjustments (the “Avenue Warrants”). In addition, Avenue may convert up to $<span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20230321__20230321__dei--LegalEntityAxis__custom--AvenueMember_znqPhvQd54Vh" title="Debt conversion amount">2</span> million of the $<span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_z602PgTCG9Fi" title="Proceeds from line of credit">15</span> million in term loans funded at closing into shares of the Company’s common stock at any time while the loans are outstanding, at a price per share equal to $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230321__dei--LegalEntityAxis__custom--AvenueMember_zCzZmapiVAi1" title="Conversion price">1.49</span>. Proceeds from the Avenue Facility were used to repay the Company’s outstanding notes payable balances with CRG Financial and are expected to be used for general corporate purposes. <span id="xdx_900_eus-gaap--LineOfCreditFacilityDescription_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_z347WKMnmv8c" title="Line of credit, description">The Company is subject to certain affirmative and negative covenants under the Avenue Facility, including the requirement, beginning on the closing date, to maintain at least $5 million of unrestricted cash to be tested at the end of each month, and beginning on the period ended September 30, 2023, and at the end of each quarter thereafter, a trailing six-month cash flow, subject to certain adjustments as provided by the Avenue Credit Agreement, of at least $2 million.</span> As of December 31, 2023, there was $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumMonthendOutstandingAmount_pn6n6_c20231230__20231231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_z8p2JafxiEZ2" title="Credit facility outstanding">19</span> million outstanding under the Avenue Facility, and the Company was in compliance with the Avenue Facility covenants. Loans under the Avenue Facility accrue interest at a variable rate per annum equal to the greater of <span id="xdx_904_eus-gaap--LineOfCreditFacilityInterestRateDescription_c20231230__20231231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zk14ZfwSdii1" title="Credit facility interest rate description">(i) the sum of 4.75% plus the Prime Rate (as defined in the Avenue Supplement) and (ii) 12.50%. Payments are interest only for up to 24 months and then fully amortized thereafter.</span> The Avenue Facility matures on <span id="xdx_90F_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231230__20231231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zQ94fJysrkxb" title="Credit facility expire date">October 1, 2026</span>. The Company may prepay the loans, subject to a prepayment penalty of <span id="xdx_90A_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_c20231230__20231231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember__srt--RangeAxis__srt--MinimumMember_z0HFOYDNqfG7" title="Credit facility interest rate">1.00</span>% to <span id="xdx_900_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_c20231230__20231231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember__srt--RangeAxis__srt--MaximumMember_z4ChIZChlCj" title="Credit facility interest rate">3.00</span>% of the principal amount prepaid, depending on the timing of the prepayment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2023, the Company entered into a collaboration with Medifast, Inc. through and with certain of its wholly-owned subsidiaries (“Medifast”). Pursuant to certain agreements between the parties, Medifast has agreed to pay to the Company the amount of $<span id="xdx_907_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231211__dei--LegalEntityAxis__custom--MedifastIncMember_zxRrto5DYHX2" title="Collaboration amount">10</span> million to support the collaboration, funding enhancements to the Company platform, operations and supporting infrastructure, of which $<span id="xdx_90A_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231212__dei--LegalEntityAxis__custom--MedifastIncMember_z7Tk97gRuZ34" title="Collaboration amount">5</span> million was paid at the closing on December 12, 2023, and the remainder is to be paid in two $<span id="xdx_907_ecustom--BusinessCombinationRemainingConsiderationTransferred_pn5n6_c20240331__20240331__dei--LegalEntityAxis__custom--MedifastIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zI8rxKV66MB3" title="Consideration to be transferred"><span id="xdx_901_ecustom--BusinessCombinationRemainingConsiderationTransferred_pn5n6_c20240630__20240630__dei--LegalEntityAxis__custom--MedifastIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRFTYlKdRpTd" title="Consideration to be transferred">2.5</span></span> million installments on March 31, 2024 and June 30, 2024 (or earlier upon the Company’s achievement of certain program milestones) (the “Medifast Collaboration”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in connection with the Medifast Collaboration, the Company entered into a stock purchase agreement and registration rights agreement with Medifast’s wholly-owned subsidiary, Jason Pharmaceuticals, Inc., whereby the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--MedifastPrivatePlacementMember_zUBmYwXvrxZ2" title="Shares issued">1,224,425</span> shares of its common stock in a private placement (the “Medifast Private Placement”) at a purchase price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20231211__us-gaap--TypeOfArrangementAxis__custom--MedifastPrivatePlacementMember_zWUVGNNjbZV4" title="Shares issued per share">8.1671</span> per share, for aggregate proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--MedifastPrivatePlacementMember_zmexY0F8P0Vf" title="Proceeds">10</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, on June 8, 2021, the Company filed a shelf registration statement on Form S-3 under the Securities Act, which was declared effective on June 22, 2021 (the “2021 Shelf”). Under the 2021 Shelf at the time of effectiveness, the Company originally had the ability to raise up to $<span id="xdx_909_eus-gaap--DebtSecurities_iI_pn6n6_c20210608__us-gaap--StatementEquityComponentsAxis__custom--SharesAndSecuritiesMember_z1SQ9nREiP0c" title="Raise up funds">150</span> million by selling common stock, preferred stock, debt securities, warrants, and units. In conjunction with the 2021 Shelf, the Company also entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc. and Cantor Fitzgerald & Co. relating to the sale of its common stock. In accordance with the terms of the ATM Sales Agreement, the Company may, but is not obligated to, offer and sell, from time to time, shares of common stock, through or to the Agents, acting as agent or principal. Sales of common stock, if any, will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act. As of December 31, 2023, the Company had $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_z1cWvTiGm9m6" title="Proceeds from sale of securities">53.3</span> million available under the ATM Sales Agreement and $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyOneShelfMember_zrMl1SpPPgDk" title="Proceeds from sale of securities">32.0</span> million available under the 2021 Shelf.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a current cash balance of approximately $<span id="xdx_904_eus-gaap--Cash_iI_pn5n6_c20240311_zq4v7wuxGgF8" title="Cash">26.4</span> million as of the filing date.The Company reviewed its forecasted operating results and sources and uses of cash used in management’s assessment, which included the available financing and consideration of positive and negative evidence impacting management’s forecasts, market, and industry factors. Positive indicators that lead to its conclusion that the Company will have sufficient cash over the next 12 months following the date of this report include: (1) its continued strengthening of the Company’s revenues and improvement of operational efficiencies across the business, (2) the expected improvement in its cash burn rate over the next 12 months and positive operating cash flows during the year ended December 31, 2023, (3) positive working capital of $<span id="xdx_90D_ecustom--WorkingCapital_iI_pn5n6_c20231231_zCRt6yo0f1Ac" title="Working capital">7.8</span> million as of December 31, 2023, (4) cash on hand of $<span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_znvvCP7yrMcb" title="Cash in hand">33.1</span> million as of December 31, 2023, (5) $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_zucmmc2OMPBg" title="Proceeds from sale of securities">53.3</span> million available under the ATM Sales Agreement and $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyOneShelfMember_z8748YWYnMU7" title="Proceeds from sale of securities">32.0</span> million available under the 2021 Shelf, (6) management’s ability to curtail expenses, if necessary, and (7) the overall market value of the telehealth industry and how it believes that will continue to drive interest in the Company already evidenced by the Medifast Collaboration and Private Placement noted above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	460000	usd
CY2022Q1	LFMD	Mile Stone Payment MileStonePayment	3460000	usd
CY2022Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	507000	usd
CY2022Q1	LFMD	Asset Acquisition Closing AssetAcquisitionClosing	62500	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-214300000	usd
CY2024Q1	us-gaap	Cash Cash	26400000	usd
CY2023Q4	LFMD	Working Capital WorkingCapital	7800000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	33100000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zcdEBQHe98hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zLtgOiukdfh9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include returns and allowances, stockholders’ equity-based transactions, the capitalization and impairment of capitalized software and impairment of other long-lived assets, estimates to cash flow projections, and liquidity assessment. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2023Q4	LFMD	Subscription Price Per Share SubscriptionPricePerShare	1.95
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152547006	usd
CY2023	LFMD	Concentration Risk Percentage ConcentrationRiskPercentage	1	pure
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119033520	usd
CY2022	LFMD	Concentration Risk Percentage ConcentrationRiskPercentage	1	pure
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	8800000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	5500000	usd
CY2023Q4	LFMD	Increase In Deferred Revenue IncreaseInDeferredRevenue	3300000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	8800000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	5500000	usd
CY2023Q4	LFMD	Deferred Revenue Balances From Previous Year DeferredRevenueBalancesFromPreviousYear	4800000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5547506	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1499880	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	58319435	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	37410617	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	55038343	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	33362991	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8828598	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5547506	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	528000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	815000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	356000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	161000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1898784	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2587370	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1216833	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1276891	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	355685	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	160898	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2759932	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3703363	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	486000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	127000	usd
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	63000	usd
CY2023Q4	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	11800000	usd
CY2022Q4	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	8800000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	8000000.0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8000000.0	usd
CY2022	LFMD	Principal Of Paycheck Protection Program Loans Forgiven PrincipalOfPaycheckProtectionProgramLoansForgiven	63000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11294345	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10766676	shares
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zIpd07CGUmo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zyvkSyLCV1bg">Concentrations of Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits. We are dependent on certain third-party manufacturers and pharmacies, although we believe that other contract manufacturers or third-party pharmacies could be quickly secured if any of our current manufacturers or pharmacies cease to perform adequately. As of December 31, 2023, we utilized three (3) suppliers for fulfillment services, nine (9) suppliers for manufacturing finished goods, seven (7) suppliers for packaging, bottling, and labeling, and five (5) suppliers for prescription medications. As of December 31, 2022, we utilized four (4) suppliers for fulfillment services, six (6) suppliers for manufacturing finished goods, five (5) suppliers for packaging, bottling, and labeling, and three (3) suppliers for prescription medications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2022Q1	LFMD	Business Combination Consideration Transferred BusinessCombinationConsiderationTransferred	9100000	usd
CY2022Q1	LFMD	Business Combination Cash Paid Upfront BusinessCombinationCashPaidUpfront	1000000.0	usd
CY2022Q1	LFMD	Business Combination Future Payable BusinessCombinationFuturePayable	3000000.0	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	5100000	usd
CY2022Q1	LFMD	Business Combination Potential Earn Out BusinessCombinationPotentialEarnOut	72800000	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9091762	usd
CY2022Q1	LFMD	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Customer Relationship Intangible Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipIntangibleAsset	918812	usd
CY2022Q1	LFMD	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Name Intangible Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeNameIntangibleAsset	133339	usd
CY2022Q1	LFMD	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Developed Technology Intangible Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopedTechnologyIntangibleAsset	12920	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	7168	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	37888	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets	354000	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	408030	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	8035665	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	8000000.0	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	5100000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8000000.0	usd
CY2022Q1	LFMD	Asset Acquisition Closing AssetAcquisitionClosing	62500	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8000000.0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3015435	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2043971	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3009263	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3831859	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	971000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	927000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	5198123	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3508883	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	3003007	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	576027	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2501035	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2501035	usd
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	776563	usd
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	776563	usd
CY2023Q4	LFMD	Purchase Price Payable One PurchasePricePayableOne	641042	usd
CY2022Q4	LFMD	Purchase Price Payable One PurchasePricePayableOne	2463002	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	448718	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1817724	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1892281	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13937494	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12166509	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	217000000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	0	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	334000	usd
CY2023Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	79330	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	LFMD	Undesignated Preferred Stock UndesignatedPreferredStock	3385000	shares
CY2021Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	55300000	usd
CY2023	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	2.21875
CY2023	LFMD	Percentage Of Preferred Stock Liquidation Preference PercentageOfPreferredStockLiquidationPreference	0.08875	pure
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2023	us-gaap	Dividends Dividends	3100000	usd
CY2022	us-gaap	Dividends Dividends	3100000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The Series A Preferred Stock is perpetual and has no maturity date. No outstanding shares of Series A Preferred Stock have been redeemed. However, the Series A Preferred Stock will be redeemable at our option, in whole or in part, at the following redemption prices, plus any accrued and unpaid dividends up to, but not including, the date of redemption: 1) on and after October 15, 2022 and prior to October 15, 2023, at a redemption price equal to $25.75 per share, 2) on and after October 15, 2023 and prior to October 15, 2024, at a redemption price equal to $25.50 per share, 3) on and after October 15, 2024 and prior to and prior to October 15, 2025 at a redemption price equal to $25.25 per share and 4) on and after October 15, 2025 at a redemption price equal to $25.00 per share. In addition, upon the occurrence of a delisting event or change of control, we may, subject to certain conditions, at our option, redeem the Series A Preferred Stock, in whole or in part within 90 days after the first date on which such delisting event occurred or within 120 days after the first date on which such change of control occurred, as applicable, by paying $25.00 per share, plus any accumulated and unpaid dividends up to, but not including, the redemption date.
CY2023Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	25.00
CY2023	LFMD	Cashless Exercise Of Options Shares CashlessExerciseOfOptionsShares	74372	shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	37500	shares
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	94500	usd
CY2023	LFMD	Stock Issued During Period Shares Cash Less Warrants Exercised StockIssuedDuringPeriodSharesCashLessWarrantsExercised	79330	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	90400	shares
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	90400	usd
CY2022	LFMD	Cashless Exercise Of Options Shares CashlessExerciseOfOptionsShares	29691	shares
CY2022	LFMD	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	22000	shares
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	38500	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	2600000	usd
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.32
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	306250	shares
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	400000	shares
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	594897	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	603180	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73849	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2100000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	628813	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	68850	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	20634	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	677029	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	861000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	871000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	897883	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	773952	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M4D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M25D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0717	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0715	pure
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023	us-gaap	Short Term Lease Payments ShortTermLeasePayments	3000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	3000	usd
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	63000	usd
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	400000	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	100000	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	400000	shares
CY2023Q3	LFMD	Number Of Additional Shares Issued NumberOfAdditionalSharesIssued	100000	shares
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.32
CY2023Q3	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	1900000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	100800000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5400000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11800000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	111000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6700	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	317000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	428000	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	6700	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1470000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1719000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1470000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1365000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	354000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	428000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360700	usd
CY2023	LFMD	Expected Tax Expense Benefit ExpectedTaxExpenseBenefit	-1951000	usd
CY2022	LFMD	Expected Tax Expense Benefit ExpectedTaxExpenseBenefit	-9474000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-440000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-714000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	71000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	730000	usd
CY2023	LFMD	Effective Income Tax Rate Reconciliation Tax Apportionment Of Puerto Rico Income EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome	-133000	usd
CY2022	LFMD	Effective Income Tax Rate Reconciliation Tax Apportionment Of Puerto Rico Income EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome	-108000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	1855000	usd
CY2023	us-gaap	Income Tax Reconciliation Deductions Dividends IncomeTaxReconciliationDeductionsDividends	1224000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4327000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9973000	usd
CY2023	LFMD	Income Tax Reconciliation Rate Differential IncomeTaxReconciliationRateDifferential	-2125000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	48000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-46300	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	428000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360700	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11646000	usd
CY2023Q4	LFMD	Deferred Tax Asset Software Development DeferredTaxAssetSoftwareDevelopment	-298000	usd
CY2022Q4	LFMD	Deferred Tax Asset Software Development DeferredTaxAssetSoftwareDevelopment	-142000	usd
CY2023Q4	LFMD	Deferred Tax Assets Temporary Differences DeferredTaxAssetsTemporaryDifferences	-2465000	usd
CY2022Q4	LFMD	Deferred Tax Assets Temporary Differences DeferredTaxAssetsTemporaryDifferences	-2389000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23057000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21382000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40920000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35559000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40920000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35559000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152547006	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119033520	usd
CY2023	LFMD	Gross Margin GrossMargin	0.8706	pure
CY2022	LFMD	Gross Margin GrossMargin	0.843	pure
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-14489273	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-43447781	usd
CY2023Q4	us-gaap	Assets Assets	58480709	usd
CY2022Q4	us-gaap	Assets Assets	25665853	usd

Files In Submission

Name	View Source	Status
0001493152-24-009581-index-headers.html	Edgar Link	pending
0001493152-24-009581-index.html	Edgar Link	pending
0001493152-24-009581.txt	Edgar Link	pending
0001493152-24-009581-xbrl.zip	Edgar Link	pending
ex10-110.htm	Edgar Link	pending
ex10-110_001.jpg	Edgar Link	pending
ex10-110_002.jpg	Edgar Link	pending
ex10-110_003.jpg	Edgar Link	pending
ex10-110_004.jpg	Edgar Link	pending
ex10-110_005.jpg	Edgar Link	pending
ex10-110_006.jpg	Edgar Link	pending
ex10-110_007.jpg	Edgar Link	pending
ex10-110_008.jpg	Edgar Link	pending
ex10-110_009.jpg	Edgar Link	pending
ex10-110_010.jpg	Edgar Link	pending
ex10-110_011.jpg	Edgar Link	pending
ex10-110_012.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
ex97_001.jpg	Edgar Link	pending
ex97_002.jpg	Edgar Link	pending
ex97_003.jpg	Edgar Link	pending
ex97_004.jpg	Edgar Link	pending
ex97_005.jpg	Edgar Link	pending
ex97_006.jpg	Edgar Link	pending
ex97_007.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
lfmd-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
lfmd-20231231_def.xml	Edgar Link	unprocessable
lfmd-20231231_lab.xml	Edgar Link	unprocessable
lfmd-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
lfmd-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LFMD
LifeMD, Inc. Stock $lfmd

2024 Q1 Form 10-K Financial Statement

#000149315224009581 Filed on March 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFMD LifeMD, Inc. Stock $lfmd

2024 Q1 Form 10-K Financial Statement

#000149315224009581 Filed on March 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFMD
LifeMD, Inc. Stock $lfmd